Medtronic announced results from two studies evaluating the utility of atherectomy for peripheral endovascular interventions.
NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through ...
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical innovation company accelerating high-impact technologies ...
The 2024 edition of Transcatheter Cardiovascular Therapeutics (TCT) once again highlighted significant innovations in ...
Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Lemaitre Vascular (LMAT – Research Report) today and set a price target of ...
Medtronic and Volcano Corporation. Peripheral vascular devices Market Outlook Peripheral vascular devices are gadgets used in the diagnosis and management of diseases of the blood vessels other ...
Zacks.com on MSN5d
Medtronic Stock Trading at a Discount Before Q2 Earnings: Time to Buy?Medtronic plc MDT is scheduled to report second-quarter fiscal 2025 results on Nov. 19, before the opening bell. In the last reported quarter, the company’s adjusted earnings of $1.23 exceeded the ...
Medtronic (NYSE:MDT) announced results from two studies evaluating the utility of atherectomy for peripheral endovascular interventions.
Discover why LeMaitre's expansion in the peripheral vascular disease market and strong dividend growth make it an appealing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback